Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Integrated Wealth Concepts LLC

Integrated Wealth Concepts LLC reduced its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 6.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,950 shares of the company’s stock after selling 143 shares during the quarter. Integrated Wealth Concepts LLC’s holdings in Neurocrine Biosciences were worth $225,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the business. 1832 Asset Management L.P. boosted its stake in Neurocrine Biosciences by 1,370.7% during the 2nd quarter. 1832 Asset Management L.P. now owns 541,200 shares of the company’s stock worth $74,507,000 after purchasing an additional 504,400 shares during the period. Los Angeles Capital Management LLC raised its holdings in shares of Neurocrine Biosciences by 639.6% in the third quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company’s stock valued at $48,479,000 after buying an additional 363,863 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of Neurocrine Biosciences by 23.0% during the second quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company’s stock worth $166,959,000 after buying an additional 228,444 shares during the period. Renaissance Technologies LLC grew its holdings in shares of Neurocrine Biosciences by 9.6% during the second quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company’s stock worth $339,790,000 after buying an additional 216,500 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in Neurocrine Biosciences by 40.3% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 710,600 shares of the company’s stock valued at $97,828,000 after acquiring an additional 203,934 shares during the period. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Neurocrine Biosciences Stock Down 0.1 %

NASDAQ NBIX opened at $126.70 on Friday. Neurocrine Biosciences, Inc. has a fifty-two week low of $110.95 and a fifty-two week high of $157.98. The business has a fifty day moving average of $121.49 and a 200-day moving average of $130.78. The stock has a market cap of $12.83 billion, a price-to-earnings ratio of 33.97 and a beta of 0.34.

Insiders Place Their Bets

In other Neurocrine Biosciences news, insider Jude Onyia sold 2,331 shares of the firm’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $126.29, for a total value of $294,381.99. Following the sale, the insider now directly owns 15,449 shares of the company’s stock, valued at approximately $1,951,054.21. This trade represents a 13.11 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 4.30% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Piper Sandler upgraded shares of Neurocrine Biosciences from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $131.00 to $159.00 in a research report on Thursday, August 29th. StockNews.com cut shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. Raymond James reiterated an “outperform” rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Royal Bank of Canada reduced their price target on Neurocrine Biosciences from $136.00 to $133.00 and set a “sector perform” rating for the company in a report on Friday, October 4th. Finally, Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a research note on Monday, November 11th. Five research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $165.18.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.